NYLIM
VKTX icon

New York Life Investment Management’s Viking Therapeutics VKTX Stock Holding History

New York Life Investment Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-11,097
Closed -$447K – 849
2024
Q4 		$447K Sell
11,097
-881
-7% -$50.2K ﹤0.01% 788
2024
Q3 		$758K Buy
11,978
+672
+6% +$39.4K 0.01% 753
2024
Q2 		$599K Buy
+11,306
New +$741K 0.01% 789

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

New York Life Investment Management's VKTX Position: Q1 2025 in Review

New York Life Investment Management sold out of Viking Therapeutics (VKTX) in Q1 2025, closing a stake of 11,097 shares — an estimated $447K sold.

New York Life Investment Management first reported a position in VKTX in Q2 2024 and held it in 3 quarters. The position peaked at $758K in Q3 2024. 372 funds tracked by Wall St. Rank hold VKTX as of Q1 2025.

  • New York Life Investment Management reported no remaining Viking Therapeutics position as of Q1 2025 after selling out during the quarter.
  • New York Life Investment Management sold 11,097 Viking Therapeutics shares in Q1 2025, an estimated $447K.
  • New York Life Investment Management first reported a position in Viking Therapeutics in Q2 2024 and held it in 3 quarters.
  • New York Life Investment Management's Viking Therapeutics position peaked at $758K in Q3 2024.
  • 372 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2025.

Based on New York Life Investment Management's 13F filing for Q1 2025, filed 8 May 2025.